Ciancio Ciancio Brown, P.C.
(303) 872-8919
(800) 746-3560

Leaders in Litigation

Colorado company acquires private Italian company

A biopharmaceutical company in Colorado recently announced they are acquiring a privately held company in Italy. Clovis Oncology, based out of Boulder, said they will pay $200 million for the acquisition of EOS S.p.A. 

Why did the company want to acquire the Italian company? EOS owns the rights to lucitanib, which is used in treatments for certain types of cancer. Through the acquisition, Clovis Oncology will now have the rights to develop and commercialize lucitanib in the United States and Japan. Clovis Oncology will have to work with the company that owns the rights in China since EOS sublicensed the rights to the drug to a company in China last year.

The CEO of Clovis Oncology said they had been interested in this drug for a while and acquired the Italian company to be able to use the drug in their current research and programs. 

Clovis Oncology agreed to pay $200 million for EOS. The purchase price is $10 million in cash, and the rest of the purchase will be in stock in Clovis Oncology. In addition to the cash and stock, Clovis Oncology will also pay $65 million in cash after the U.S. Food and Drug Administration initially approves lucitanib in the U.S. 

The acquisition should be very beneficial for the Colorado company. After the acquisition was announced, the company's stock increased by almost 17 percent. 

This is an example of how companies in Colorado can acquire other businesses to help their own mission and stock. Acquisitions can be a complicated legal issue for many companies, especially when you are dealing with a business outside of the U.S. It is very important to understand the impact acquiring the business will have on your financial portfolio before making any final decisions.  

Source: Denver Business Journal, "Clovis Oncology pays $200M for Italian company," L. Wayne Hicks, Nov. 20, 2013

Email us your case details

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Broomfield Office
390 Interlocken Crescent
Suite 350
Broomfield, CO 80021

Phone: 303-451-0300
Fax: 303-464-8000
Map & Directions

Denver Office
1660 Lincoln Street
Suite 2000
Denver, Colorado 80264

Phone: 303-451-0300
Fax: 303-464-8000
Map & Directions

Breckenridge Office
106 North French Street
Suite 230
Breckenridge, CO 80424

Phone: 303-451-0300
Fax: 303-464-8000
Map & Directions

Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters.